<DOC>
	<DOCNO>NCT01750281</DOCNO>
	<brief_summary>The purpose study treat patient locally advance metastatic NSCLC combination therapy selumetinib two different dos docetaxel 75mg/m2 60 mg/m2 v placebo compare well dose affect cancer respond . It also help u understand tolerability profile different dose regimen patient</brief_summary>
	<brief_title>Assess Efficacy Safety AZD6244 Combination With Docetaxel Patients Receiving Second Line Non Small Cell Lung Cancer Treatment .</brief_title>
	<detailed_description>A Phase II , Double-Blind , Randomised , Placebo-Controlled Study Assess Efficacy Safety Selumetinib ( AZD6244 ; ARRY-142886 ) ( Hyd-Sulfate ) Combination Docetaxel , Compared Placebo Combination Docetaxel , Patients receive second line treatment Locally Advanced Metastatic Non Small Cell Lung Cancer ( Stage IIIB - IV )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Provision sign , write date informed consent prior study specific procedure Male female , age 18 year old Histological cytological confirmation locally advance metastatic NSCLC ( IIIBIV ) Prospective confirmation KRAS mutation negative status determine via AZ approve laboratory Failure 1st line anticancer therapy due radiological documentation disease progression advance disease subsequent relapse disease follow 1st line therapy Mixed small cell nonsmall cell lung cancer histology Received &gt; 1 prior anticancer drug regimen advance metastatic NSCLC . Patients develop disease progression switch maintenance therapy ( maintenance use agent firstline regimen ) eligible . Other concomitant anticancer therapy agent except steroid Prior treatment MEK ( MitogenActivated Protein Kinase ) inhibitor docetaxelcontaining regimen ( prior treatment paclitaxel acceptable ) The last radiation therapy within 4 week prior start study treatment , limited field radiation palliation within 7 day first dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mitogen-Activated Protein Kinase Kinase inhibitor</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Second line treatment Non Small Cell Lung Cancer</keyword>
</DOC>